Omar S. Al‐Odat

This study identifies phosphorylation as a mechanism protecting oncogenic RAS from LZTR1-mediated degradation, with implications for targeting RAS stability in hematologic cancers.

This paper identifies KS18, a Mcl-1 inhibitor, as a potential treatment for multiple myeloma, showing it enhances apoptosis and overcomes resistance to bortezomib and venetoclax in resistant cells and mouse models.

This paper develops a novel BTK inhibitor, KS151, which effectively targets MM stem cell-like cells and enhances the response to chemotherapeutic agents.